Papargyriou A, Najajreh M, Cook DP, et al. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma (PMID: 39658630). Nat Biomed Eng. 2024.
Category: Publication
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (GeparNuevo)
Denkert C, Schneeweiss A, Rey J, et al. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (GeparNuevo) (PMID: 39566464). Cell Rep Med. 2024.
Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism
Cheytan T, Schneider M, Wurth R, et al. Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism (PMID: 40057730). Mol Cancer. 2025.
IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis
Denk D, Ramakrishnan M, Conche C, et al. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis (PMID: 40023157). Immunity. 2025.
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping (PenelopeB)
Denkert C, Rachakonda S, Karn T, et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping (PenelopeB) (PMID: 39933898). Cancer Cell. 2025.
Study protocol of the METAPANC trial – intensified treatment in patients with local operable but oligometastatic pancreatic cancer – multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
Ghadimi M, Pelzer U, Besselink MG, et al. Study protocol of the METAPANC trial – intensified treatment in patients with local operable but oligometastatic pancreatic cancer – multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial (PMID: 39915735). BMC Cancer. 2025.
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response
Hofer S, Frasch L, Brajkovic S, et al. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response (PMID: 39838187). Mol Syst Biol. 2025.
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
Keyl J, Keyl P, Montavon G, et al. Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence (PMID: 39885364). Nat Cancer. 2025.
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA
Metzenmacher M, Zaun G, Trajkovic-Arsic M, et al. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA (PMID: 39478658). Mol Oncol. 2025.
Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility
Schwerd-Kleine P, Wurth R, Cheytan T, et al. Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility (PMID: 40022208). Int J Cancer. 2025.
